Navigation Links
Overweight and obese patients less likely to achieve remission in early RA
Date:6/14/2013

Madrid, Spain, 14 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that overweight and obese patients are less likely to achieve successful remission in early rheumatoid arthritis (ERA) compared to those of normal weight.

Obese and overweight ERA subjects required 2.4 times more anti-TNF therapy throughout the study than normal weight participants without achieving similar remission outcomes.

RA is a chronic, inflammatory autoimmune disease affecting approximately 1 in 100 people worldwide. RA can cause pain, stiffness, progressive joint destruction and deformity, and reduce physical function, workability, quality of life and life expectancy. At least 50% of RA patients in developed countries are unable to hold down a full-time job within 10 years of onset.2

Obesity continues to remain one of the greatest public health challenges of the 21st century; numbers of those affected rise each year, with the disease now causing 10󈝹% of deaths in Europe.3

"Obesity and rheumatoid arthritis are both on the rise, with devastating effects on individuals and society as a whole. These data reinforce the link between obesity and inflammation, and establish that BMI is one of the few modifiable variables influencing the major outcomes in RA," said Elisa Gremese, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome. "There is an urgent need to address the issues of overweight and obesity to improve patients' chance of successful remission."

346 ERA patients with symptom duration <12 months were categorized into one of three BMI classes (normal weight, overweight and obese) and treated according to a treat-to-target strategy aimed at remission. The strategy included strict follow-up visits, treatment with methotrexate up to 25mg/week+steroids, and combination with a TNF blocker if at least a good response according to EULAR criteria* was not obtained.

Data demonstrate that overweight and obese patients reached a lower rate of remission, both with DAS and CDAI criteria, at 6 and 12 month follow-up visits. A higher percentage of obese and overweight ERA patients were under anti-TNF treatment after 12 months of follow-up compared to normal weight.


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Obese patients trust diet advice from overweight physicians more than normal-weight physicians
2. Study Finds Overweight Young Males Have a Greater Risk of Not Surviving Until Age 55, Making Weight Loss Supplements Like Prescopodene Helpful With Increasing Longevity
3. Study: Physicians less likely to bond with overweight patients
4. Overweight While Younger Ups Kidney Risk Later
5. Overweight Cops in Sydney Ordered to Trim Down
6. South Jersey Health and Body Explains the Dangers of Diabetes and What You Must Know if You are Overweight
7. Soccer Kicks Up Activity Level of Overweight Kids: Study
8. Allergy Rescue Shots May Work Better in Lower Thigh of Overweight Kids
9. Poll: Many Americans Dont See Their Kids as Overweight
10. Could Being a Little Overweight Help You Live Longer?
11. Overweight Teens Report High Rates of Bullying, Teasing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider ... planning assistance to clients in southern Montana, is announcing a focused charity effort ... , The outreach programs offered by Zoo Montana provide students with current knowledge ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... assistance and financial consultations to communities in northern Virginia and DC, is announcing ... help provide for patients with Alzheimer’s and other disorders that lead to memory ...
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, ... Finnegan to the position of Executive Vice President, Sales and Marketing. Finnegan is ... telehealth and medical device sales leadership. He has received industry recognition for innovations ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the cloud-based payment platform ... industry’s hospitals and provider groups, has announced that it will now offer Parasail’s ... is a San Francisco health-finance startup that has launched a series of tech-based ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... , June 16, 2017 Datascope Corp. is voluntarily performing ... Corp. for a potential electrical test failure code.     ... PART NUMBER ... CS300 IABP 0998-UC-0446HXX; ... This ...
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
Breaking Medicine Technology: